The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia

Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiolo...

Descripción completa

Detalles Bibliográficos
Autor principal: Hughes, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126330/
https://www.ncbi.nlm.nih.gov/pubmed/35663170
http://dx.doi.org/10.6004/jadpro.2022.13.3.32
_version_ 1784712103035142144
author Hughes, David
author_facet Hughes, David
author_sort Hughes, David
collection PubMed
description Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting.
format Online
Article
Text
id pubmed-9126330
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-91263302022-06-04 The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia Hughes, David J Adv Pract Oncol Meeting Reports Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126330/ /pubmed/35663170 http://dx.doi.org/10.6004/jadpro.2022.13.3.32 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Hughes, David
The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
title The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
title_full The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
title_fullStr The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
title_full_unstemmed The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
title_short The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
title_sort 4 t's of itp: tailoring therapies to treat thrombocytopenia
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126330/
https://www.ncbi.nlm.nih.gov/pubmed/35663170
http://dx.doi.org/10.6004/jadpro.2022.13.3.32
work_keys_str_mv AT hughesdavid the4tsofitptailoringtherapiestotreatthrombocytopenia
AT hughesdavid 4tsofitptailoringtherapiestotreatthrombocytopenia

Ejemplares similares